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ABSTRACT 
The circadian glucocorticoid-Krüppel-like factor 15-branched-chain amino acid (GC-KLF15-BCAA) signaling pathway is 
a key regulatory axis in muscle, whose imbalance has wide-reaching effects on metabolic homeostasis. Spinal muscular 
atrophy (SMA) is a neuromuscular disorder also characterized by intrinsic muscle pathologies, metabolic abnormalities 
and disrupted sleep patterns, which can influence or be influenced by circadian regulatory networks that control 
behavioral and metabolic rhythms. We therefore set out to investigate the contribution of the GC-KLF15-BCAA pathway 
in SMA pathophysiology of Taiwanese Smn-/-;SMN2 and Smn2B/- mouse models. We thus uncover substantial 
dysregulation of GC-KLF15-BCAA diurnal rhythmicity in serum, skeletal muscle and metabolic tissues of SMA mice. 
Importantly, modulating the components of the GC-KLF15-BCAA pathway via pharmacological (prednisolone), genetic 
(muscle-specific Klf15 overexpression) and dietary (BCAA supplementation) interventions significantly improves 
disease phenotypes in SMA mice. Our study highlights the GC-KLF15-BCAA pathway as a contributor to SMA 
pathogenesis and provides several treatment avenues to alleviate peripheral manifestations of the disease. The 
therapeutic potential of targeting metabolic perturbations by diet and commercially available drugs could have a broader 
implementation across other neuromuscular and metabolic disorders characterized by altered GC-KLF15-BCAA 
signaling.  
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HIGHLIGHTS 
• SMA is a neuromuscular disease characterized by motoneuron loss, muscle abnormalities and metabolic 
perturbations.  
• The regulatory GC-KLF15-BCAA pathway is dysregulated in serum and skeletal muscle of SMA mice during 
disease progression. 
• Modulating GC-KLF15-BCAA signaling by pharmacological, dietary and genetic interventions improves 
phenotype of SMA mice.  
RESEARCH IN CONTEXT 
Spinal muscular atrophy (SMA) is a devastating and debilitating childhood genetic disease. Although nerve cells are 
mainly affected, muscle is also severely impacted. The normal communication between the glucocorticoid (GC) 
hormone, the protein KLF15 and the dietary branched-chain amino acids (BCAAs) maintains muscle and whole-body 
health. In this study, we identified an abnormal activity of GC-KLF15-BCAA in blood and muscle of SMA mice. 
Importantly, targeting GC-KLF15-BCAA activity with an existing drug or a specific diet improved disease progression in 
SMA mice. Our research uncovers GCs, KLF15 and BCAAs as therapeutic targets to ameliorate SMA muscle and 
whole-body health. 
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INTRODUCTION 
Transcriptional regulation is one of the main control mechanisms of metabolic processes (Desvergne et al., 2006). 
Krüppel-like factor 15 (KLF15) is a transcription factor expressed in a multitude of metabolic tissues including skeletal 
muscle (Gray et al., 2002) where it is involved in regulation of lipid (Haldar et al., 2012), glucose (Gray et al., 2007), and 
amino acid metabolism (Jeyaraj et al., 2012). Specifically, KLF15 displays a diurnal pattern of expression, and regulates 
branched-chain amino acids (BCAA) metabolism and utilization in a circadian fashion (Jeyaraj et al., 2012). BCAAs 
(isoleucine, leucine and valine) are a major source of essential amino acids in muscle (35%) (Harper et al., 1984). 
Accumulating evidence in various species suggest that BCAAs promote survival, longevity (D’Antona et al., 2010; 
Valerio et al., 2011) and repair of exercise- and sarcopenia-induced muscle damage  (Morley et al., 2010; Shimomura 
et al., 2004). Both KLF15 and BCAAs are modulated by circadian secretion of glucocorticoids (GCs) and activity of the 
glucocorticoid receptor (GR) (Masuno et al., 2011; Shimizu et al., 2011). GCs are also used surreptitiously by endurance 
athletes for their ergogenic properties (Duclos, 2010) and as treatment for genetic muscle pathologies (Mendell et al., 
1989).  
 
The neuromuscular disease spinal muscular atrophy (SMA) is the most common autosomal recessive disorder leading 
to infant mortality (D’Amico et al., 2011). It is characterized by degeneration of α-motoneurons in the ventral horn of the 
spinal cord as well as progressive muscle weakness and atrophy (Crawford and Pardo, 1996; Pearn, 1978). SMA is a 
monogenic disease caused by homozygous deletions or mutations within the survival motor neuron 1 (SMN1) gene 
(Brzustowicz et al., 1990; Lefebvre et al., 1995). Complete loss of SMN is embryonic lethal in mice (Schrank et al., 
1997). However, humans have at least one copy of the highly homologous SMN2 gene, which generates a low amount 
of functional protein that allows for embryonic development, while not being sufficient for complete rescue in the event 
of SMN1 loss. This is due to a nucleotide transition in SMN2 that favors alternative splicing of exon 7 and production of 
a non-functional truncated protein (Lefebvre et al., 1995; Lorson et al., 1999; Monani et al., 1999). Whilst several cellular 
functions for SMN have been defined (Boyer et al., 2010; Hensel and Claus, 2017; Li et al., 2014), it remains elusive 
why a lack of the ubiquitously expressed SMN results in the canonical SMA phenotype.  
 
Although motoneurons are the primary cellular targets in SMA, a number of tissues outside the central nervous system 
(CNS) also contribute to disease pathophysiology (Hamilton and Gillingwater, 2013), with skeletal muscle being the 
most prominently afflicted (Boyer et al., 2014). As muscle plays an important role in maintaining systemic energy 
homeostasis (Baskin et al., 2015), intrinsic muscle defects can have severe consequences on whole-body metabolism. 
Various studies in SMA animal models and patients report metabolic abnormalities such as abnormal fatty acid 
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metabolism (Crawford et al., 1999; Dahl and Peters, 1975; Tein et al., 1995), defects in glucose metabolism and 
pancreatic development (Bowerman et al., 2014; Melissa Bowerman et al., 2012b) and the coexistence of diabetes 
mellitus and diabetic ketoacidosis in SMA patients (Borkowska et al., 2015; Lamarca et al., 2013). The observation that 
dietary supplementation improves lifespan of SMA mice (Butchbach et al., 2014, 2010; Narver et al., 2008) further 
supports the hypothesis that metabolic perturbations contribute to SMA pathology. We thus postulate that intrinsic 
metabolic defects in skeletal muscle play a contributory role in whole-body metabolic perturbations in SMA.  
 
Here, we identify dysregulation of the GC-KLF15-BCAA pathway in skeletal muscle as a key pathological event in SMA. 
Notably, we demonstrate that pharmacological and dietary interventions that modulate this pathway lead to significant 
phenotypic improvements in SMA mice. Our results reveal the importance of the GC-KLF15-BCAA axis in SMA 
pathogenesis and highlight its potential as a therapeutic target to attenuate muscle and metabolic disturbances in SMA. 
The accessibility and ease of administration of the dietary and drug treatments identified in our study make them exciting 
clinical avenues to investigate not only in SMA patients but also in individuals with other neuromuscular and 
neurodegenerative diseases where GC-KLF15-BCAA signaling may be altered.    
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MATERIALS AND METHODS 
Animals 
The Taiwanese Smn-/-;SMN2 (FVB/N background, FVB.Cg-Smn1tm1HungTg(SMN2)2Hung/J, RRID: J:59313), Smn2B/- 
(C57BL/6 background, RRID: not available) and KLF15 MTg (C57BL/6 background, RRID: not available) mice were 
housed either in individual ventilated cages in the typical holding rooms of the animal facility or in circadian isolation 
cages (12 hr light:12 hr dark cycle, LD12:12). Experiments with the Smn-/-;SMN2 and Klf15 MTg mice were carried out 
in the Biomedical Sciences Unit, University of Oxford, according to procedures authorized by the UK Home Office 
(Animal Scientific Procedures Act 1986). Experiments with the Smn2B/-  mice were carried out at the University of Ottawa 
Animal Facility according to procedures authorized by the Canadian Council on Animal Care.  Prednisolone (5 mg 
tablets, Almus) was dissolved in water (1 tablet in 5 mL) and administered by gavage on every second day starting at 
P0 until death in the severe Taiwanese Smn-/-;SMN2 SMA mouse model. In the Smn2B/- mouse model, prednisolone or 
saline was administered by gavage every two days from P0 to P20. For the Smn2B/- mouse model treatment, weaned 
mice were given daily wet chow at the bottom of the cage to ensure proper access to food. BCAA peptides (Myprotein) 
were diluted in water (300 mg in 2 mL) and administered to the severe Taiwanese Smn-/-;SMN2 SMA mice by gavage 
starting at P5. Pip6a-PMO and Pip6a-scrambled compounds were delivered by facial vein injections at P0 and P2 (10 
ug/g diluted in 0.9% saline) to WT and severe Taiwanese Smn-/-;SMN2 SMA mice. Prednisolone and BCAAs were 
administered to the animals around the same time each day.  Litters were randomly assigned to treatment prior to birth. 
For survival studies, animals were weighed daily and culled upon reaching their defined humane endpoint. To reduce 
total number of animals used, the fast-twitch tibialis anterior and triceps muscles from the same animal were used 
interchangeably for respective molecular and histological analyses. Sample sizes were determined based on similar 
studies with SMA mice. 
 
Peptide-PMO synthesis 
Pip6a Ac-(RXRRBRRXRYQFLIRXRBRXRB)-COOH was synthesized and conjugated to a PMO chemistry as previously 
described (Hammond et al., 2016). The full length SMN2 enhancing PMO (5′-ATTCACTTTCATAATGCTGG- 
3′) and scrambled PMO (5′- TACGTTATATCTCGTGATAC-3′) sequences were purchased from Gene Tools LLC. 
 
qPCR 
Skeletal muscles were harvested at several time-points during disease progression and immediately flash frozen. For 
circadian experiments, liver, heart, white and brown adipose tissue (WAT and BAT), spinal cord and tibialis anterior 
muscles were harvested from P2 and P7 pups every 4 hrs over a 24 hr period (ZT1 = 9 am, ZT5 = 1 pm, ZT9 = 5 pm, 
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ZT13 = 9 pm, ZT17 = 1 am, ZT21 = 5 am). RNA was extracted with the RNeasy MiniKit (Qiagen) except for WAT and 
BAT where the RNeasy Lipid Tissue MiniKit (Qiagen) was used. Reverse transcription was performed using the High-
Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). qPCR was performed either using TaqMan Gene 
Expression Mastermix (ThermoFisher Scientific) or SYBR green Mastermix (ThermoFisher Scientific) and primers were 
from Integrated DNA Technologies (see Supplementary Experimental Procedures). For SYBR green qPCRs, RNA 
polymerase II polypeptide J (PolJ), was used as a validated housekeeping gene. PolJ has previously been demonstrated 
as being stably expressed between tissues and in different pharmacological conditions (Radonić et al., 2004). For 
circadian experiments and TaqMan qPCRs, housekeeping genes for each tissue were determined using the Mouse 
geNorm Kit and qbase+ software (Primerdesign).  
 
PCR arrays 
RNA from skeletal muscle was extracted using the RNeasy Microarray Tissue Mini Kit (Qiagen). cDNA was made using 
RT2 First Strand Kit (Qiagen). qPCRs were performed using Mouse Amino Acid Metabolism I & II PCR arrays (PAMM-
129Z and PAMM-130Z, SABiosciences). Data was analyzed with the RT Profiler PCR Array Data Analysis version 3.5 
and mRNA expression was normalized to the geometric average of the two most stably expressed housekeeping genes 
between all samples. 
 
Immunoblots with mouse tissues 
Triceps were isolated from P7 Smn-/-;SMN2 mice and healthy control littermates and snap frozen in liquid nitrogen. The 
tissue was lysed in 200 μl RIPA buffer (150 mM NaCl, 50 mM Tris, 0.5% sodium deoxycholate, 0.1% TX-100, 5 mM 
sodium pyrophosphate, 2 mM β-glycerophosphate, 1×EDTA-free protease inhibitor (Roche), 1×PhosSTOP 
phosphatase inhibitor (Roche), pH 7.5) using Precellys 24 homogenizer (Stretton Scientific). Total protein (20 μg per 
lane) was resolved on Tris-glycine SDS-PAGE and transferred to PVDF membrane. The following antibodies were used: 
p70 S6 kinase (#2708, RRID: AB_390722), S6 Ribosomal Protein (#2217, RRID: AB_331355), Phospho-S6 Ribosomal 
Protein (Ser235/236, #2211, RRID: AB_331679) (all 1:1000, Cell Signaling Technology), and goat anti-rabbit IRDye 
800CW (#827-08365, LI-COR Biosciences, RRID: AB_10796098). The membranes were imaged and quantified using 
ImageStudio and LI-COR Odyssey Fc (LI-COR Biosciences). Band intensities were normalized to total protein as 
determined by Fast Green (FG) stain (125 μM Fast Green FCF, 6.7% acetic acid, 30% methanol) (Luo et al., 2006). 
Each biological sample (n) was run in 3-4 technical replicates and the average of all technical replicates was used to 
determine the final relative expression for each biological sample.  
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Corticosterone ELISA 
Analysis of corticosterone content in serum was performed with an ELISA kit (#ab108821, Abcam) following the 
manufacturer's instructions. Serum samples were diluted 1:10.  
 
BCAA content in muscle and serum 
Levels of valine, leucine and isoleucine were measured in muscle and serum by high-performance liquid 
chromatography (HPLC) (AltaBiosciences, Birmingham, UK). Skeletal muscles were pooled to reach a minimum weight 
of 100 mg and sera were pooled to reach a minimum volume of 150 L. 
 
Neuromuscular junction (NMJ) immunohistochemistry 
NMJs were stained as previously described (Bowerman et al., 2010). Briefly, whole tibialis anterior muscle was 
harvested and fixed in 4% paraformaldehyde (PFA) for 15 min. Muscles were incubated with α-bungarotoxin (α-BTX) 
conjugated to tetramethylrhodamine (#BT00012, Biotium, 1:100, RRID: not available) at RT for 30 min with ensuing 
PBS washes. Muscles were incubated in blocking solution (0.2% Triton-X, 2% BSA, 0.1% sodium azide) at RT for 1 hr. 
Nerve terminals were stained with antibodies against synaptic vesicle 2 (#SV2 (Supernatant 1 mL), Developmental 
Studies Hybridoma Bank, 1:100, RRID: AB_2315387) and neurofilament NF-M (#2H3, Supernatant 1 mL), 
Developmental Studies Hybridoma Bank, 1:100, RRID: AB_2314897) overnight at 4°C. Following three PBS washing 
steps, the tissue was incubated with an Alexα Fluor 488 goat anti-mouse antibody (#A-21141, Molecular Probes, 1:500, 
RRID:AB_141626) at RT for 1 hr. Finally, 2-3 thin filets per muscle were sliced and mounted in Fluoromount-G (Southern 
Biotech). Images were taken with a confocal microscope, with a 20X objective, equipped with filters suitable for 
FITC/Cy3 fluorescence. The experimenter quantifying NMJ morphology and innervation was blinded to the genotype of 
the animals until all measurements were finalized.  
 
Human samples 
Skeletal muscle biopsies from SMA patients and controls were obtained from two different biobanks (Fondazione IRCCS 
Istituto Neurologico "C. Besta" and Fondazione Ospedale Maggiore Policlinico Mangiagalli en Regina Elena, IRCCS) 
(Mutsaers et al., 2011). As previously described, protein was extracted in RIPA buffer with 10% protease inhibitor 
cocktail (Sigma). Equal amounts of total protein were loaded and blocked in Odyssey buffer (LI-COR Biosciences). 
Membranes were incubated overnight with the primary antibody goat anti-KLF15 (#ab2647, Abcam, 1:1000, RRID: 
AB_303232). The secondary antibody was rabbit anti-Goat IgG (H+L) DyLight 800 (#SA5-10084, Thermo Fisher 
Scientific, RRID: AB_2556664). Membranes were imaged on a LI-COR Odyssey FC imager and analyzed with Image 
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StudioTM software (LI-COR Biosciences). Coomassie staining of the gel was used to visualize total protein, which was 
used as a normalization control. 
 
Statistics 
All statistical analyses were performed using GraphPad Prism version 6.0h software. When appropriate, a student’s 
unpaired two-tailed t-test, a one-way ANOVA followed by a Tukey’s multiple comparison test or a two-way ANOVA 
followed by a Sidak’s multiple comparison test was used. Outliers were identified via the Grubbs' test and subsequently 
removed. For the Kaplan-Meier survival analysis, a log-rank test was used and survival curves were considered 
significantly different at p<0.05 where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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RESULTS 
Dysregulation of the GC-KLF15-BCAA axis in severe SMA mice 
We first investigated the GC-KLF15-BCAA pathway in skeletal muscle from severe Smn-/-;SMN2 SMA mice (Hsieh-Li 
et al., 2000). Muscles were selected based on their vulnerability to neuromuscular junction (NMJ) denervation (from 
most vulnerable to resistant: triceps > gastrocnemius (gastro) > tibialis anterior (TA) > quadriceps femoris (quad)) (Ling 
et al., 2012). Muscles were harvested from Smn-/-;SMN2 and wild type (WT) mice at several time-points during disease 
progression (post-natal day (P) 0: birth, P2: pre-symptomatic, P5: early symptomatic, P7: late symptomatic, P10: end 
stage). As GCs exert their influence on KLF15 via GR, we assessed expression of the two GR isoforms α and β (Hinds 
et al., 2010) in muscle of P2 and P7 mice. GRα is thought to be a key mediator of GC-dependent target gene 
transactivation, while GRβ inhibits GRα and induces GC resistance (Hinds et al., 2016). Interestingly, we observed a 
significant downregulation of GRα mRNA in P2 and upregulation of GRβ mRNA in P7 Smn-/-;SMN2 mice compared to 
WT (Fig. 1a, b), with the exception of P7 quad where GRβ is significantly decreased in SMA animals. Both, GRβ and 
GRα mRNA levels are not significantly different between Smn-/-;SMN2  and WT mice at P2 and P7, respectively 
(Supplementary Fig. 1a, b), with the exception of P7 gastro where GRα is significantly decreased in SMA animals.  
 
We next examined the expression profile of Klf15 mRNA during disease progression and found the same pattern in all 
four muscles: decreased levels in P2 and increased levels in P7 Smn-/-;SMN2 mice compared to WT animals (Fig. 1c).  
Interestingly, the peak expression of Klf15 mRNA in WT muscles occurs at P2 while in SMA muscles, it is observed at 
P5 or later, reflecting a potential developmental delay, which has previously been reported for myogenic regulatory 
factors (MRFs) (Boyer et al., 2014; Bricceno et al., 2014). To evaluate if similar developmental delays also occurred for 
GRa and GRb mRNA expression, we further determined their expression profiles at all time-points during disease 
progression. Interestingly, we observed peak levels at P2 for both GRa and GRb mRNAs for most WT muscles 
(Supplementary Fig. 2). However, in SMA muscles, GRa and GRb mRNA levels either remained similar throughout or 
displayed a slight downregulation/upregulation in symptomatic stages (Supplementary Fig. 2). Thus, the expression 
profiles of GR and GR mRNAs are distinct from that of Klf15 mRNA. 
 
We next wanted to determine if the increased Klf15 mRNA expression corresponded to previously reported differential 
Smn expression during neonatal muscle development in a different severe SMA mouse model (Monani et al., 2000). 
We find that Smn mRNA levels do not significantly change in WT muscles from P0 to P10, with the exception of a 
significant increase in P2 quad (Supplementary Fig. 3). Our findings are consistent with another study demonstrating 
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that Smn protein levels in hindlimb muscles from WT animals are relatively high and similar from P0 to P10, followed by 
a dramatic decrease from P10 onwards (Boyer et al., 2014). 
 
Seeing as aberrant Klf15 expression may alter BCAA metabolism, we performed commercially available Amino Acid 
Metabolism PCR arrays on P2 and P7 triceps (Supplementary table 1). We observed that the expression of a number 
of effectors of BCAA metabolism were significantly downregulated in P2 and upregulated in P7 Smn-/-;SMN2 mice 
compared to WT animals (Fig. 1d). These included Bcat2 mRNA, the major catabolic enzyme of BCAAs (Harper et al., 
1984), previously shown to be regulated by KLF15 activity (Jeyaraj et al., 2012). We next evaluated Klf15 mRNA 
expression in heart and liver of P2 and P7 animals, two metabolic tissues highly influenced by KLF15 activity (Gray et 
al., 2007; Zhang et al., 2015). Klf15 mRNA levels were unchanged in tissues from P2 mice but were significantly 
increased in heart and liver from P7 Smn-/-;SMN2 mice compared to WT animals (Fig. 1e). Therefore, our results suggest 
that the decreased activity of the GC-KLF15-BCAA pathway in pre-symptomatic SMA mice is limited to skeletal muscle, 
whereas the increased activity in symptomatic SMA animals may be a more widespread phenomenon. 
 
Maintenance of muscle function and mass throughout life depends on the balance between protein synthesis and 
degradation regulated by mammalian target of rapamycin (mTOR) (Saxton and Sabatini, 2017). Amino acid availability, 
particularly the BCAA leucine, stimulates mTOR complex 1 (mTORC1) protein synthesis in muscle (Saxton and Sabatini, 
2017). KLF15 thus interferes with mTOR protein synthesis by promoting BCAT2 activity and subsequent degradation of 
leucine (Shimizu et al., 2011). We therefore investigated mTOR activity in skeletal muscle (triceps) of P7 Smn-/-;SMN2 
mice and control littermates, which, to the best of our knowledge, has not yet been performed in the Taiwanese SMA 
mouse model. Ribosomal protein S6 kinase beta-1 (S6K1) is phosphorylated (p) following mTOR activation and 
subsequently directly phosphorylates the S6 ribosomal protein (S6) (Saxton and Sabatini, 2017). As direct downstream 
effectors, both S6K1 and S6 were therefore used to assess mTOR activity. Immunoblot analysis revealed that protein 
levels of S6K1, p-S6 and S6 are significantly downregulated in triceps of Smn-/-;SMN2 mice compared to healthy 
littermates (Fig. 1f, g). Thus, the mTOR-dependent protein synthesis is significantly downregulated in SMA muscle, 
which could be directly linked to the upregulated Klf15 mRNA levels.  
  
We also obtained human muscle biopsies (gastrocnemius) from control non-SMA individuals and SMA Type I-III patients 
(most severe to less severe: Type I > Type II > Type III) of varying ages (3 mths-27 yrs). Western blot analysis of KLF15 
protein revealed a trend for increased KLF15 levels in SMA muscle samples (Fig. 1h, Supplementary Fig. 4). These 
protein expression patterns therefore prompt further detailed studies of GC-KLF15-BCAA signaling in SMA patients. 
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Finally, we wanted to assess if dysregulation of Klf15, GR and GR mRNAs was linked to SMN levels. To do so, we 
used muscle from Smn-/-;SMN2 mice that received facial vein injections at P0 and P2 of our previously published Pip6a- 
phosphorodiamidate oligomer (PMO) compound that promotes full length SMN production from the human SMN2 gene 
(Hammond et al., 2016). P7 TAs from Pip6a-PMO-treated Smn-/-;SMN2 mice were compared to age-matched tissues 
from WT animals as well as untreated and Pip6a-scrambled-treated Smn-/-;SMN2 mice. Interestingly, we find that Klf15 
mRNA is significantly reduced in in both Pip6a-PMO and Pip6a-scrambled-treated muscles (Supplementary Fig. 5a), 
suggesting an SMN-independent normalization of Klf15 mRNA levels. Indeed, our combined qPCR, transcriptomics and 
proteomics analysis of these tissues shows that while the Pip6a-scrambled compound does not increase FL SMN2 
mRNA expression, numerous transcripts and proteins are significantly differentially regulated compared to muscle from 
untreated SMA mice (data not shown). The aberrant expression of Klf15 mRNA and its restoration in Pip6a-treated 
muscle may therefore be more related to overall muscle and whole-body metabolic state and activity (Fan et al., 2017; 
Tanaka et al., 2017). Both Pip6a-PMO and Pip6a-scrambled had no normalization effects on GR mRNA levels 
(Supplementary Fig. 5b) while similar SMN-independent effects were observed for GR mRNA levels (Supplementary 
Fig. 5c).  
Altered diurnal expression of the GC-KLF15-BCAA pathway in severe SMA mice 
All components of the GC-KLF15-BCAA pathway display functional and regulatory circadian expression patterns 
(Dickmeis, 2009; Jeyaraj et al., 2012). As our analysis so far corresponds to a single time-point during a 24 hr period, 
we next assessed the circadian rhythmicity of the GC-KLF15-BCAA axis in SMA mice. Upon pairing, breeding pairs 
were entrained to a 12 hr light:12 hr dark cycle (LD12:12) and ensuing litters maintained in that environment. Serum, 
TA and triceps were harvested from P2 and P7 Smn-/-;SMN2 and Smn+/-;SMN2 control littermates every 4 hrs (Zeitgeber 
time, ZT) over a 24 hr period (ZT0 = 8 am, ZT1 = 9 am, ZT5 = 1 pm, ZT9 = 5 pm, ZT13 = 9 pm, ZT17 = 1 am, ZT21 = 5 
am). Corticosterone (major mouse GC) levels in serum were measured by ELISA at ZT5 (day) and ZT17 (night) and 
show significantly dysregulated levels in Smn-/-;SMN2 mice defined by elevated release in the dark phase compared to 
control littermates (Fig. 2a). Assessment of GR gene expression in TA shows that the diurnal pattern of GRα mRNA is 
relatively similar between Smn-/-;SMN2 mice and control littermates (Fig. 2b). However, GRβ mRNA displays significant 
changes in amplitude, whereby we observe similar oscillation patterns but with differential expression at specific ZTs in 
both P2 and P7 Smn-/-;SMN2 mice compared to control littermates (Fig. 2c). The overall upregulation of GRβ known to 
mediate metabolic GC resistance (Hinds et al., 2016, 2010) may be a compensatory mechanism to counteract the 
aberrant GC regulation identified in Fig. 2a. Analysis of diurnal expression of Klf15 mRNA also shows changes in 
amplitude with a general downregulation in P2 and upregulation in P7 Smn-/-;SMN2 mice compared to control littermates 
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(Fig. 2d). The fact that GRα/β and Klf15 levels are similar between groups at certain ZTs could suggest that the defect 
lies in circadian regulation and not overall expression as well as highlights discrepancies in data interpretation that can 
arise when circadian effectors are analyzed at one single time-point.  
 
To determine if circadian BCAA metabolism was impacted, valine, leucine and isoleucine levels were measured by high-
performance liquid chromatography (HPLC) in serum and triceps of P2 and P7 Smn-/-;SMN2 mice and control littermates 
over a 24 hr period. In muscle, we report diurnal cycling of BCAAs in P2 and P7 mice with changes in phase (distinct 
oscillation patterns) and amplitude at both time-points between Smn-/-;SMN2 mice and control littermates (Fig. 2e), with 
the exception of isoleucine at P7. Similar observations were made when looking at serum BCAA levels, where the 24 
hr cycling behaviour in P2 and P7 Smn-/-;SMN2 mice demonstrates differences in phase and amplitude compared to 
control littermates (Fig. 2f), with the exception of isoleucine at P2. Of particular interest is the generalized depletion of 
all BCAAs in the serum of P7 Smn-/-;SMN2 animals (Fig. 2f), which may reflect the high use in skeletal muscle due to 
increased Klf15 expression at the same time-point (Fig. 2d).  
 
Finally, to assess if aberrant circadian expression of Klf15 mRNA was specific to skeletal muscle, we evaluated its 
rhythmicity in various metabolic tissues (white adipose tissue (WAT), brown adipose tissue (BAT), liver and heart) and 
spinal cord (SC) from P2 and P7 Smn-/-;SMN2  mice and control littermates (Supplementary Fig. 6). We find changes in 
phase and amplitude in all P2 tissues except for SC while at P7, all tissues display significant phase and amplitude 
alterations highlighted by an overall significant increase in Klf15 mRNA expression. These systemic alterations in Klf15 
expression could further influence the serum depletion of BCAAs observed in P7 Smn-/-;SMN2 mice (Fig. 2f). Combined, 
our results demonstrate a dysregulated circadian regulation of the GC-KLF15-BCAA pathway in Smn-/-;SMN2 mice, 
which is specific to skeletal muscle in the pre-symptomatic stage and evolves to a whole-body phenomenon as disease 
progresses.  
Altogether, our analysis of GC-KLF15-BCAA signaling during disease progression (Fig. 1) and over a 24 hr period (Fig. 
2), demonstrate an overall downregulated activity in pre-symptomatic muscle and upregulated activity in symptomatic 
muscle (Fig. 3), which could potentially have distinct effects on the development and/or maintenance of muscle and 
metabolic pathologies in SMA. 
Modulating upstream GC-KLF15-BCAA signaling with prednisolone improves phenotype of severe SMA mice 
We next set out to determine if aberrant regulation of Klf15 mRNA in Smn-/-;SMN2 mice has a physiological impact on 
major disease phenotypes. Firstly, to counteract the muscle-specific downregulation of Klf15 mRNA in pre-symptomatic 
 14 
Smn-/-;SMN2 mice (Fig. 1c, 2d), we used the pharmacological compound prednisolone, a synthetic GC previously 
demonstrated to specifically induce Klf15 mRNA expression (Morrison-Nozik et al., 2015; Quattrocelli et al., 2017a). We 
administered prednisolone by gavage to Smn-/-;SMN2 mice and control littermates every 2 days starting at P0. A dose-
response assessment of prednisolone (2.5, 5 and 10 mg/kg) determined the optimal dose of 5 mg/kg (Supplementary 
Fig. 7). We firstly validated the direct action of prednisolone on the GC-KLF15-BCAA pathway in muscle of P2 and P7 
Smn-/-;SMN2 mice and control littermates. We found that the expression of total GR mRNA (Nr3c1, GR + GR) is 
significantly reduced in P2 and P7 prednisolone-treated mice compared to untreated animals (Fig. 4a), most likely 
attributed to a GC-mediated downregulation of GR gene transcription (Rosewicz et al., 1988). Further analysis revealed 
that this downregulation was specifically attributed to a decreased expression of GR mRNA as GR mRNA levels were 
unchanged (Fig. 4b). As total GR mRNA levels are consistently significantly less abundant than GR mRNA levels, 
the latter will therefore have greater impact on total GR (Nr3c1) mRNA levels. As expected, Klf15 mRNA levels are 
significantly enhanced in P2 Smn-/-;SMN2 mice and control littermates treated with prednisolone compared to untreated 
animals (Fig. 4c). At P7 however, Klf15 mRNA is significantly upregulated in prednisolone-treated control littermates 
compared to untreated mice while no changes are seen in prednisolone-treated Smn-/-;SMN2 mice (Fig. 4c), suggesting 
that Klf15 signaling in SMA mice becomes less responsive to GCs as disease progresses, potentially as a result of the 
increased expression of GRβ (Fig. 1b, 2c). Finally, mRNA levels of the direct transcriptional target of KLF15, Bcat2 
(Gray et al., 2007) were unchanged in P2 Smn-/-;SMN2 mice and control littermates (Fig. 4d), most likely reflecting the 
delayed increase of Bcat2 expression following Klf15 induction (Shimizu et al., 2011). Indeed, we detected a significant 
upregulation of Bcat2 mRNA in muscles from P7 prednisolone-treated Smn-/-;SMN2 mice and control littermates 
compared to untreated animals (Fig. 4d).  
 
Importantly, we demonstrate that Smn-/-;SMN2 animals display a significant increased weight gain (Fig. 4e) and an 
enhanced lifespan after prednisolone administration (Fig. 4f). In contrast, control littermates mice show a significant 
weight reduction when treated with prednisolone (Fig. 4g), which could be attributed to the typical muscle wasting effect 
of prolonged exposure to GCs (Goldberg and Goodman, 1969). Thus, our results suggest that modulating GC-KLF15-
BCAA signaling with a synthetic GC is a valid therapeutic strategy for SMA. 
 
Modulating GC-KLF15-BCAA signaling with prednisolone improves phenotype of intermediate SMA mice 
To investigate whether the observed dysregulation in the GC-KLF15-BCAA axis is present in other SMA mouse models, 
we repeated key experiments in the intermediate Smn2B/- mice (Mélissa Bowerman et al., 2012; Hammond et al., 2010). 
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Similar to the severe SMA mouse model, Smn2B/- mice display a significant reduction in Klf15 mRNA expression in pre-
symptomatic muscle (TA) followed by a significant upregulation during disease progression compared to age-matched 
WT animals (Fig. 5a). Using commercially available Amino Acid Metabolism PCR arrays (Supplementary table 1), we 
also demonstrate perturbed expression of BCAA metabolism effectors, particularly in symptomatic Smn2B/- mice where 
several genes are significantly increased compared to WT animals (Fig. 5b). Interestingly, we noted a comparable 
upregulation of Bcat2, Oxct2a, Acat1, Acadsb and Mut mRNAs in symptomatic severe Smn-/-;SMN2 and intermediate 
Smn2B/- SMA mice (Fig. 5c). Importantly, we also administered prednisolone (5 mg/kg) by gavage to Smn2B/- mice and 
Smn2B/+ control littermates every 2 days from P0 to P20. This dosing regimen had a significant beneficial effect on weight 
gain (Fig. 5d) and led to an enhanced lifespan (Fig. 5e) of treated Smn2B/- mice compared to saline-treated animals. 
Prednisolone had no significant impact on weight of Smn2B/+ control littermates (Fig. 5f). We thus show a dysregulated 
Klf15 pathway in muscle of two distinct SMA mouse models, and importantly demonstrate that modulating the GC-
KLF15 signaling cascades via administration of prednisolone improves weight and survival in both Smn-/-;SMN2 and 
Smn2B/- mice. 
Prednisolone improves neuromuscular phenotype of severe SMA mice 
 
Having shown that GC treatment ameliorates SMA disease progression in intermediate and severe SMA mouse models, 
we further analyzed the effects of prednisolone on neuromuscular pathology in P7 Smn-/-;SMN2 mice and control 
littermates. We first assessed the effect of prednisolone on the expression of MuRF-1 and atrogin-1 mRNAs, ubiquitin 
ligases involved in muscle atrophy (Bodine et al., 2001) and typically induced by chronic administration of GCs 
(Schakman et al., 2013). Expression of mRNA of both atrogenes is significantly increased in treated control littermates 
compared to untreated control animals while no differences are found between prednisolone-treated and untreated Smn-
/-;SMN2 mice (Fig. 6a, b). The GC induction of MuRF-1 and atrogin-1 mRNAs in healthy animals only may explain the 
reduced weights specifically observed in prednisolone-treated control littermates (Fig. 4g).  
 
We next investigated the impact of prednisolone on expression of MyoD, myogenin and parvalbumin mRNAs, 
determinants of muscle health previously involved in SMA muscle pathology (Boyer et al., 2014; Bricceno et al., 2014; 
Mutsaers et al., 2011). MyoD and myogenin are myogenic regulatory factors (MRFs) that modulate commitment to 
muscle lineage and muscle-specific gene expression (Sassoon et al., 1989). Parvalbumin is a marker for neuromuscular 
perturbations as its expression is decreased in denervated muscles (Müntener et al., 1985) and in symptomatic muscle 
of SMA patients and Smn-/-;SMN2 mice (Mutsaers et al., 2011). We found that MyoD mRNA expression is significantly 
enhanced in muscle of prednisolone-treated Smn-/-;SMN2 mice compared to untreated animals while GCs did not impact 
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MyoD mRNA levels in control littermates (Fig. 6c). In contrast, prednisolone caused a significant reduced expression of 
myogenin mRNA in control littermates while no significant changes in expression were observed between treated and 
untreated Smn-/-;SMN2 mice (Fig. 6d). The downregulation of myogenin mRNA in control littermates treated with 
prednisolone may reflect the increased atrophy signaling (Jogo et al., 2009) (Fig. 6a, b) and weight loss (Fig. 4g) 
specifically observed in this experimental cohort. Interestingly, comparison of parvalbumin mRNA expression in Smn-/-
;SMN2 mice and control littermates shows that prednisolone significantly increases parvalbumin mRNA levels in both 
groups (Fig. 6e), which in SMA mice has previously been associated with improved muscle health (Mutsaers et al., 
2011).  
 
We then wanted to determine if molecular changes generated by prednisolone administration would ameliorate the 
denervation pathology and developmental defects at the neuromuscular junction (NMJ) (Murray et al., 2008). 
Assessment of NMJs in TAs of P7 animals showed a significant reduction in motor endplate area of untreated Smn-/-
;SMN2 mice compared to untreated control littermates, which remained unchanged in prednisolone-treated Smn-/-
;SMN2 animals (Fig. 6f). Interestingly, treated control animals display a significantly smaller endplate area compared to 
untreated control littermates (Fig. 6f), again depicting the adverse impact of prednisolone on muscle of control animals. 
Next, we examined endplate morphology by distinguishing between plaque-like and perforated endplates, whereby in 
the maturation process, their shape changes from plaque-like at P0, to perforated at P5, and finally to pretzel-like at P10 
(Sanes and Lichtman, 2001). We find that both treated and untreated Smn-/-;SMN2 mice display significantly more 
immature appearing endplates compared to treated and untreated control littermates (Fig. 6g). Finally, we quantified 
the innervation status of endplates and demonstrate that prednisolone significantly increases the number of fully 
innervated NMJs in Smn-/-;SMN2 mice compared to untreated animals (Fig. 6h). Interestingly, prednisolone has 
previously been demonstrated to play a beneficial role in the pre-synaptic compartment of the NMJ, by preventing a 
drug-induced neuromuscular blockade (Dal Belo et al., 2002). The improved NMJ innervation may also be associated 
with the increased parvalbumin expression observed in muscle of prednisolone-treated Smn-/-;SMN2 mice (Fig. 6e), 
known to reflect the denervation status of muscle (Müntener et al., 1985). Taken together, our molecular and 
histopathological analyses reveal a differential response to prednisolone between Smn-/-;SMN2 mice and control 
littermates. Muscles from control animals undergo a GC-induced atrophy, while this pathway is not activated in SMA 
mice. Rather, Smn-/-;SMN2 muscles show a myogenic response and a restoration of fully innervated endplates, which 
potentially explain the ameliorated phenotype of prednisolone-treated Smn-/-;SMN2 mice. 
Synergistic effect of prednisolone and Klf15 overexpression on muscle pathology of SMA mice 
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To better evaluate the impact of prednisolone-dependent Klf15 induction in SMA animals, we generated transgenic 
Smn-/-;SMN2 mice that overexpress Klf15 specifically in skeletal muscle by crossing the SMA line with the previously 
described KLF15 MTg mice (Morrison-Nozik et al., 2015). The ensuing F1 litters generated Smn-/-;SMN2, Smn+/-;SMN2, 
Smn-/-;SMN2;KLF15 MTg and Smn+/-;SMN2;KLF15 MTg mice that were on a mixed background of C57BL/6 (KLF15 
MTg line) and FVB/N (Smn-/-;SMN2 line). We first assessed the activity of the skeletal muscle specific 
enhancer/promoter (muscle creatine kinase (MCK)) driving Klf15 expression in P2 and P7 tissues. We found a significant 
increased expression of Klf15 mRNA in the quadriceps muscle of both P2 and P7 Smn-/-;SMN2;KLF15 MTg and Smn+/-
;SMN2;KLF15 MTg mice (Fig. 7a). To determine how this upregulation of Klf15 affected GC-KLF15-BCAA signaling, we 
analyzed the expression of total GR (Nr3c1, GR + GR) and Bcat2 mRNAs in quadriceps from P7 animals. While total 
GR mRNA expression is lower in SMA animals, it is not influenced by Klf15 overexpression (Fig. 7b). Here again, the 
decreased expression of total GR mRNA levels in SMA mice reflects the more abundant GRa mRNA, which is also 
significantly decreased in Smn-/-;SMN2 and Smn-/-;SMN2;KLF15 MTg mice (Fig. 7c), and not that of the GR mRNA 
isoform, which is similar between all groups (Fig. 7d). However, Bcat2 mRNA is similarly increased in both Smn-/-
;SMN2;KLF15 MTg and Smn+/-;SMN2;KLF15 MTg mice (Fig. 7e), suggesting that increased KLF15 activity directly 
impacts BCAA metabolism. We next determined if overexpression of Klf15 influenced markers of muscle atrophy and 
pathology in the quadriceps of P7 animals. We observed that the mRNA expression of atrogenes atrogin-1 and MurRF-
1 was not significantly different between Smn-/-;SMN2 and Smn-/-;SMN2;KLF15 MTg (Fig. 7f, g). Interestingly, 
overexpression of Klf15 in control littermates did not increase atrogin-1 or MuRF-1 mRNA levels (Fig. 7f, g), which was 
observed in prednisolone-treated Smn+/-;SMN2 mice (Fig. 6a, b). The GC-dependent induction of atrophy in control 
littermates is therefore most likely KLF15-independent. We also did not observe any KLF15-dependent changes in Myod 
and myogenin mRNA expression (Fig. 7h, i), suggesting that the difference observed in prednisolone-treated Smn-/-
;SMN2 mice (Fig. 6c, MyoD mRNA) and control littermates (Fig. 6d, myogenin mRNA) are probably due to KLF15-
independent effect of the synthetic GC. Finally, we find a partial restoration of parvalbumin mRNA expression in Smn-/-
;SMN2;KLF15 MTg animals compared to Smn-/-;SMN2 mice and control littermates (Fig. 7j). 
 
Given that our results highlight potential KLF15-dependent and-independent effects of prednisolone, we next compared 
weight and survival of untreated and prednisolone-treated Smn-/-;SMN2, Smn+/-;SMN2, Smn-/-;SMN2;KLF15 MTg and 
Smn+/-;SMN2;KLF15 MTg mice. We firstly observed that Smn-/-;SMN2;KLF15 MTg mice have a significantly greater 
lifespan than Smn-/-;SMN2 animals (Fig. 7k), highlighting a KLF15-dependent impact on disease phenotypes. 
Interestingly, prednisolone-treated Smn-/-;SMN2;KLF15 MTg mice have a significantly longer lifespan than Smn-/-
;SMN2;KLF15 MTg mice and Smn-/-;SMN2 mice treated with prednisolone (Fig. 7k), suggesting a synergistic effect of 
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transgenic Klf15 overexpression and prednisolone. Comparison of weight curves indeed reflects this, whereby Smn-/-
;SMN2;KLF15 MTg mice weigh significantly more than Smn+/-;SMN2 animals during disease progression (Fig. 7l) and 
prednisolone-treated Smn-/-;SMN2;KLF15 MTg mice show an overall increased weight gain compared to both Smn-/-
;SMN2;KLF15 MTg and prednisolone-treated Smn-/-;SMN2 animals (Fig. 7l). Finally, weight curves from control 
littermates show a small but significant weight loss in prednisolone-treated Smn+/-;SMN2;KLF15 MTg mice compared to 
Smn+/-;SMN2 and Smn+/-;SMN2;KLF15 MTg animals (Fig. 7m). Thus, prednisolone most likely acts via KLF15-
dependent and independent mechanisms, potentially in a tissue-specific and systemic manner. These results therefore 
identify the GC and the KLF15 component of the GC-KLF15-BCAA pathway as separate but interacting therapeutic 
targets for SMA. 
 
Modulating downstream GC-KLF15-BCAA signaling with BCAAs improves phenotype in severe SMA mice 
 
Having addressed the functional impact of modulating the upstream signaling cascade of the GC-KLF15-BCAA pathway 
on SMA pathology, we next wanted to evaluate if modifying downstream activity would display similar benefits. As KLF15 
is an activator of BCAA degradation by transcriptional upregulation of Bcat2, the first step in BCAA catabolism (Gray et 
al., 2007), supplementation of dietary BCAAs may counteract the upregulation of Klf15 in symptomatic Smn-/-;SMN2 
mice (Fig. 2d, Supplementary Fig. 6). To examine this, Smn-/-;SMN2 mice and control littermates received daily BCAA 
supplementation (1.5 mg/kg) by gavage, starting at P5, an early symptomatic time-point. We found that Smn-/-;SMN2 
mice treated with BCAAs display a significant increase in body weight (Fig. 8a) and lifespan (Fig. 8b) compared to 
untreated mice. Healthy controls also reveal an increased weight gain when treated with BCAAs (Fig. 8c), albeit to a 
lesser extent.  
 
Similar to our analysis with prednisolone treatment, we assessed the impact of BCAA supplementation on 
neuromuscular parameters. We first determined the effect of BCAAs on GC-KLF15-BCAA signaling and found that 
expression of total GR mRNA receptor (Nr3c1, GR + GR) was unchanged between groups (Fig. 8d). Interestingly, 
further analysis revealed a small but significant downregulation of GR mRNA levels in BCAA-treated healthy controls 
(Fig. 8e) while GR mRNA levels remained similar between groups (Fig. 8f). Whilst Bcat2 mRNA levels are unchanged 
between groups (Fig. 8h), Klf15 mRNA levels are specifically upregulated in muscle from BCAA-treated Smn-/-;SMN2 
mice (Fig. 8g). Finally, BCAA supplementation did not influence MuRF-1 (Fig. 8i), atrogin-1 (Fig. 8j), MyoD (Fig. 8k), 
myogenin (Fig. 8l) and parvalbumin (Fig. 8m) mRNA expression in Smn-/-;SMN2 mice and control littermates.  
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Interestingly, analysis of endplates reveals a BCAA-induced reduction of area in both healthy controls and Smn-/-;SMN2 
mice compared to untreated animals (Fig. 8n). However, the decreased endplate area did not impact endplate 
morphology and NMJ innervation as these remained unchanged between BCAA-treated and untreated animals, 
whereby healthy controls displayed significantly more mature perforated endplates and fully innervated NMJs (Fig. 8o, 
p). We have previously demonstrated that the size of an endplate does not correlate with its morphology (Mélissa 
Bowerman et al., 2012). Combined, our results demonstrate that symptomatic BCAA supplementation leads to 
significant benefits to a severe SMA mouse model at both a molecular and phenotypic level. While there is an obvious 
need for a better understanding of the effect of BCAAs on developing muscle and how this may be altered in SMA 
muscle and other metabolic tissues, we nevertheless provide key evidence that a dietary intervention, implemented at 
a stage when the neuromuscular decline has begun, can improve disease pathogenesis.  
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DISCUSSION 
SMA patients and animal models display diverse metabolic abnormalities (Borkowska et al., 2015; Bowerman et al., 
2014; Melissa Bowerman et al., 2012b; Crawford et al., 1999; Dahl and Peters, 1975; Lamarca et al., 2013; Tein et al., 
1995). Here, we demonstrate that aberrant expression of the GC-KLF15-BCAA pathway in SMA muscle during disease 
progression may contribute to muscle and whole-body metabolic perturbations (Argilés et al., 2016). Indeed, circadian 
dysregulation of the GC-KLF15-BCAA axis points to intrinsic and systemic metabolic dyshomeostasis. Importantly, 
through pharmacological and dietary interventions that target GC-KLF15-BCAA signaling, we were able to significantly 
improve disease phenotypes in 2 distinct SMA mouse models (Fig. 9).  
 
GC activity is mediated via the GR, which is alternatively spliced into two major isoforms: GRα and GRβ (Hollenberg et 
al., 1985). GRα is thought to be a key mediator of GC-dependent target gene transactivation, while GRβ inhibits GRα 
and induces GC resistance (Hinds et al., 2010). Recent studies have also uncovered distinct downstream effectors for 
GRα and GRβ (Kino et al., 2009), including a specific role for GRβ in skeletal muscle in the promotion of myogenesis 
and prevention of atrophy (Hinds et al., 2016). Our observed increased expression of GRβ mRNA in muscle of 
symptomatic SMA mice (Fig. 1b), may thus be a compensatory attempt to reduce the activity of catabolic pathways (e.g. 
MuRF-1 and atrogin-1) that accompanies muscle pathology in these mice. In light of SMN’s well described housekeeping 
role in mRNA splicing (Singh et al., 2017), loss of SMN could have a direct role on the splicing of GR isoforms. However, 
our analysis of SMA muscle tissue where SMN expression was restored did not reveal an SMN-dependent normalization 
of GRα and GRβ mRNA expression (Supplementary Fig. 5b, c). The dysregulated expression of GR isoforms may 
therefore result from the altered metabolic and pathological status of SMA muscle. 
 
A dysregulated metabolic state may also be responsible for the systemic increased Klf15 mRNA expression in 
symptomatic SMA mice. Indeed, Klf15 activity is directly regulated by GCs, whose key role is to maintain metabolic 
homeostasis (Kuo et al., 2013). Several metabolic perturbations have been reported in SMA animal models and patients 
(Wood et al., 2017), highlighting an existing metabolically stressed environment that could contribute to the aberrant 
KLF15 activity in SMA muscle. Seeing as KLF15 is also aberrantly regulated in the muscle disease Duchenne muscular 
dystrophy (DMD) (Morrison-Nozik et al., 2015), this transcription factor could act as a key integrator and/or biomarker 
of the metabolic and pathological state of muscle.  
 
It has previously been demonstrated that increased Klf15 in muscle promotes catabolic pathways by inhibiting the 
anabolic mTOR signaling (Shimizu et al., 2011). Our observation that the mTOR pathway is significantly downregulated 
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in muscle from symptomatic Smn-/-;SMN2 mice (Fig. 1f, g) is consistent with this pathological consequence of Klf15 
overexpression. This is concurrently accompanied by an increased expression of atrogenes (e.g. Fig.6 a, b) (Deguise 
et al., 2016). Interestingly, increased mTOR activity may be linked to decreased muscle pathology in milder forms of 
SMA (Millino et al., 2009) and loganin-induced benefits in SMA mice are associated with increased mTOR protein 
synthesis signaling in muscle (Tseng et al., 2016). 
 
Chronic GC administration is known to induce adverse metabolic effects, including wasting of skeletal muscle (van 
Raalte et al., 2009). An interesting finding throughout this study is the differential effects of GCs, whereby atrophy 
signaling was induced in healthy animals and ergogenic effects occurred in SMA mice. This dual role of GC 
administration has previously been reported in DMD mdx mice, where GCs had a similar specific benefit on diseased 
muscle (Morrison-Nozik et al., 2015).  The absence of phenotypic rescue following the genetic deletion of atrogin-1 and 
MuRF-1 in SMA mice (Iyer et al., 2014) may thus be partly explained by the altered responsiveness of atrophy signaling 
in SMA muscle. Furthermore, it was recently demonstrated that the dosing regimen itself can influence the balance 
between catabolic and anabolic effects of GCs in skeletal muscle. Indeed, intermittent dosing of GCs significantly 
improved skeletal muscle repair and function in mouse models of DMD and Limb-Girdle Muscle Dystrophy while daily 
administration of GCs promoted muscle atrophy (Quattrocelli et al., 2017b, 2017a). Thus, our dosing regimen of once 
every two days may also have enhanced the anabolic effects of prednisolone.  
 
In addition, GCs are reported to have gender-specific effects in both adult rodents and humans (Hassan-Smith et al., 
2015; Petrescu et al., 2017). While SMA is not regarded as a gender-specific disorder, several gender-specific disease 
modifiers have been reported (Howell et al., 2017; Oprea et al., 2008; Yanyan et al., 2014). Furthermore, there is also 
evidence to support that certain treatment strategies for SMA have gender-specific outcomes based on the model used 
(Howell et al., 2017).  However, in studies where neonatal rodents and horses were exposed to GCs, gender did not 
influence GC-dependent effects on glucose metabolism (systemic or skeletal muscle), body weight, locomotor activity 
or motor function (rotarod and grip strength) (Maloney et al., 2011; Valenzuela et al., 2017). As we did not discriminate 
between female and male neonates in our study, we cannot ascertain if prednisolone administration had gender-specific 
effects in the Taiwanese and Smn2B/- SMA mice, which would require a more in-depth investigation with larger sample 
sizes and independent animal models. 
 
To the best of our knowledge, there has never been a clinical trial of GCs in SMA patients. Interestingly, SMA patients 
in the adeno-associated virus serotype 9 (AAV9)-SMN1 gene therapy clinical trial also received prednisolone (1 mg/kg) 
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one day pre-gene therapy and for 30 days thereafter (Mendell et al., 2017). Although prednisolone was used for its 
immunosuppressive properties, our study suggests that it could have caused additional benefits. There therefore 
remains a need to better understand the molecular effectors and pathways induced by GCs in healthy, diseased, adult, 
developing and regenerating muscle of both males and females. 
  
Given the upregulation of KLF15 across multiple metabolic tissues and spinal cord of SMA mice, BCAA supplementation 
may have beneficial effects beyond what we observed in skeletal muscle. The decrease of serum BCAA content in 
symptomatic SMA animals suggests that the metabolic tissues are taking them up in an attempt to compensate for 
increased Klf15 activity. BCAAs and aromatic amino acids are precursors of neurotransmitters serotonin and 
catecholamines, respectively, which compete with each other at the blood-brain barrier to enter the CNS as they use 
the same transporter (Fernstrom, 2005). Reduced BCAA levels in SMA serum may increase CNS uptake of aromatic 
amino acids, directly affecting the synthesis and release of neurotransmitters and overall function. 
 
Prednisolone may also have beneficial effects beyond skeletal muscle, which is highlighted by the observed synergistic 
benefits of muscle-specific Klf15 overexpression and systemic prednisolone administration. There is indeed precedence 
for a role of prednisolone in the pre-synaptic compartment of the NMJ (Dal Belo et al., 2002), which is reflected in the 
improved endplate innervation in our prednisolone-treated SMA mice. The anti-inflammatory properties of prednisolone 
could potentially also modulate aberrant neuroinflammation and immune organ dysfunction recently reported in SMA 
animals (Deguise et al., 2017; Rindt et al., 2015; Thomson et al., 2017). Nevertheless, our observed striking upregulation 
of Klf15 expression in muscle following prednisolone administration suggests a very specific impact on KLF15 signaling. 
Indeed, the beneficial effect of glucocorticoid treatment in muscle atrophy has long been used in patients suffering from 
DMD (Angelini, 2007). This ergogenic impact has previously been attributed to the induction of the GC-KLF15 axis 
(Morrison-Nozik et al., 2015). Interestingly, a recent report has identified a synergistic effect of the RhoA/ROCK and GC 
pathways in muscle of a DMD mouse model (Mu et al., 2017). Given that we have previously demonstrated beneficial 
effects of pharmacological RhoA/ROCK inhibition on survival and neuromuscular phenotype of SMA mice (Bowerman 
et al., 2010; Melissa Bowerman et al., 2012a), the RhoA/ROCK and GC signaling cascades may equally contribute to 
muscle and metabolic pathologies in SMA muscle. Seeing as therapeutic modulation of the RhoA/ROCK pathway also 
improves disease phenotypes in neurodegenerative models such as amyotrophic lateral sclerosis and Parkinson’s 
disease (Tatenhorst et al., 2016; Tönges et al., 2014),  the perturbed GC-KLF15-BCAA activity may not be limited to 
SMA and DMD. Thus, investigations on the GC-KLF15-BCAA axis and related therapeutic strategies may have 
significant repercussions on several neuromuscular and neurodegenerative pathologies.    
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A surprising observation in our work is that dietary supplementation of BCAAs at a time-point when neurodegenerative 
and muscle atrophy events have begun is sufficient to significantly improve weight gain and survival in severe SMA 
mice. Previous studies have shown an influence of diet on SMA disease phenotype but these were fed to the mother or 
implemented at birth (Butchbach et al., 2014, 2010; Narver et al., 2008). Interestingly, several SMA patients and their 
families have adopted an amino acid (AA) diet (http://www.aadietinfo.com/), composed of elemental free form amino 
acids, including BCAAs. The claimed benefits of the AA diet in SMA patients may thus be reflected in the improved 
phenotype of SMA mice supplemented with BCAAs and be explained by a perturbed GC-KLF15-BCAA signaling. We 
are currently planning a small pilot study to investigate BCAA cycling and serum levels of SMA patients and healthy 
siblings and evaluate how this is influenced by the AA diet. BCAAs have been demonstrated to increase survival and 
longevity (D’Antona et al., 2010; Valerio et al., 2011) as well as promote exercise- and sarcopenia-induced muscle 
damage repair  (Morley et al., 2010; Shimomura et al., 2004). As such, BCAA supplementation is used by athletes 
(Gleeson, 2005) and prescribed for weight regulation(Qin et al., 2011) and management of sarcopenia (Morley et al., 
2010). Dysregulated serum levels of BCAAs have also been observed in neurodegenerative diseases such as 
Huntington’s (Mochel et al., 2007), Parkinson’s (Tosukhowong et al., 2016) and Alzheimer’s  (Ruiz et al., 2016). Thus, 
regulated BCAA supplementation or consumption may have wide-reaching benefits in several neurodegenerative and 
neuromuscular disorders.  
 
Our work has identified a key role for the GC-KLF15-BCAA axis in SMA pathogenesis, thereby identifying molecular 
targets to alleviate muscle and metabolic perturbations in SMA. Future therapeutic endeavors should consider a 
combination of pharmacological and dietary interventions to restore GC-KLF15-BCAA-dependent muscle and metabolic 
homeostasis alongside SMN-specific treatment strategies (Finkel et al., 2016; Hua et al., 2008, 2010; Passini et al., 
2011; Singh et al., 2006). Importantly, the possibility that the GC-KLF15-BCAA pathway may be disrupted in numerous 
degenerative and metabolic pathologies characterized by muscle loss and wasting combined with the commercial 
availability of targeted dietary and drug treatment strategies makes it an attractive therapeutic molecular mechanism to 
further investigate. 
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FIGURE LEGENDS 
Fig. 1: Dysregulation of the GC-KLF15-BCAA pathway in severe SMA mice and human SMA patients. a. qPCR 
analysis of GRα mRNA in four different skeletal muscles (triceps brachii (triceps), gastrocnemius (gastro), tibialis anterior 
(TA) and quadriceps femoris (quad)) of post-natal day (P) 2 Smn-/-;SMN2 mice compared to WT animals. Data represent 
mean ± SD; n = 3-4 animals per group; two-tailed t-test; triceps: p = 0.0113; gastro: p = 0.0487; TA: p = 0.0176; quad: 
p = 0.0042. b. qPCR analysis of GRβ mRNA in four different skeletal muscles of P7 Smn-/-;SMN2 mice compared to WT 
animals. Data represent mean ± SD; n = 3-4 animals per group; two-tailed t-test; triceps: p = 0.0075; gastro: p = 0.004; 
TA: p = 0.0352; quad: p = 0.0008. c. qPCR analysis of Klf15 mRNA in four different skeletal muscles of Smn-/-;SMN2 
mice compared to WT animals at P0, P2, P5, P7 and P10. Data represent mean ± SD; n = 3-4 animals per group; two-
way ANOVA; ***p<0.001, ****p<0.0001. d. BCAA metabolism effector genes (mRNA) dysregulated in triceps of P2 and 
P7 Smn-/-;SMN2 animals compared to WT mice. Data represent fold up- or downregulation with p>0.05.  e. qPCR 
analysis of Klf15 mRNA in heart and liver of P2 and P7 Smn-/-;SMN2 mice compared to WT animals. Data represent 
mean ± SD, n = 3-4 animals per group, two-way ANOVA; **p<0.01, ****p<0.0001. f. Quantification of total S6K1/total 
protein in triceps of P7 Smn-/-;SMN2 mice compared to healthy littermates. Total protein was visualized with Fast Green 
(FG) stain. Images are representative immunoblots. Data represent mean ± SD, n = 5-7 animals per group, two-tailed 
t-test; p = 0.0325. g. Quantification of phosphorylated (p)-S6 and total S6/total protein in triceps of P7 Smn-/-;SMN2 mice 
compared to healthy littermates. Total protein was visualized with Fast Green (FG) stain.  Images are representative 
immunoblots. Data represent mean ± SD, n = 5-7 animals per group, two-tailed t-test; p-S6: p = 0.0024; total S6: p = 
0.0024. h. Quantification of KLF15 protein/total protein in human gastrocnemius muscle samples from non-SMA control 
individuals and SMA Type I-III patients  
Fig. 2: Circadian rhythmicity of the GC-KLF15-BCAA axis is dysregulated in severe SMA mice. a. Corticosterone 
levels in serum of post-natal day (P) 2 and P7 Smn-/-;SMN2 mice compared to healthy control littermates at the Zeitgeber 
time (ZT) 5 and ZT17. Data represent mean ± SD; n = 3-4 animals per group, two-way ANOVA; *p<0.05 b. qPCR 
analysis of diurnal expression of GRα mRNA in the tibialis anterior (TA) of P2 and P7 Smn-/-;SMN2 mice compared to 
healthy controls. c. qPCR analysis of diurnal expression of GRβ mRNA in the TA of P2 and P7 Smn-/-;SMN2 mice 
compared to healthy controls. d. qPCR analysis of diurnal expression of Klf15 mRNA in the TA of P2 and P7 Smn-/-
;SMN2 mice compared to healthy controls. b-d: Data represent mean ± SD; n = 3-5 animals per group, two-way ANOVA; 
*p<0.05, **p<0.01, ****p<0.0001; # indicates cycling ZT1 data is duplicated.  e. Levels of the BCAAs valine, leucine and 
isoleucine in triceps of P2 and P7 Smn-/-;SMN2 and healthy controls. f. Levels of the BCAAs in serum of P2 and P7 
Smn-/-;SMN2 and healthy control animals. e-f: each data point represents the pooling of 5-15 animals. 
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Fig. 3. Schematic summarizing the activity of the glucocorticoid (GC)- glucocorticoid receptor (GR,  and )-
Klf15-BCAT2-branched-chain amino acid (BCAA) signaling cascade in normal muscle (a), pre-symptomatic 
muscle from Smn-/-;SMN2 SMA mice (b) and symptomatic muscle from Smn-/-;SMN2 SMA mice (c). 
Fig. 4: Prednisolone treatment improves disease phenotypes in severe SMA mice.  qPCR analysis of (a) Nr3c1, 
(b) GR and GR  (c) Klf15 and (d) Bcat2 mRNAs in tibialis anterior (TA) muscle of post-natal day (P) 2 and P7 untreated 
and prednisolone-treated Smn-/-;SMN2 mice and control littermates. a-d: Data represent mean ± SD; n = 3-4 animals 
per group; two-way ANOVA; *p<0.05, **p<0.01, ****p<0.0001; ns = not significant. e. Weight curves of prednisolone-
treated Smn-/-;SMN2 mice vs. untreated animals. Data represent mean ± SD; n = 10-16 animals per group; *p<0.05, 
**p<0.01. f. Lifespan of prednisolone-treated Smn-/-;SMN2 mice vs. untreated animals. Data represent Kaplan-Meier 
curves; n = 10-16 animals per group; Log-rank (Mantel-Cox) test; p = 0.0009.  g. Weight curves of prednisolone-treated 
healthy controls vs. untreated animals. Data represent mean ± SD; n = 9-18 animals per group; ****p<0.0001.  
 
Fig. 5: Dysregulation of the GC-KLF15-BCAA pathway in intermediate SMA mice and prednisolone-induced 
phenotypic improvements. a. qPCR analysis of Klf15 mRNA in tibialis anterior (TA) of Smn2B/- mice compared to WT 
animals at different ages (post-natal day (P) 0, P2, P4, P11 and P19). Data represent mean ± SD; n = 4 animals per 
group; two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001; ns = not significant. b. BCAA metabolism effector genes 
(mRNA) dysregulated in TAs of pre- and symptomatic Smn2B/- mice compared to WT animals. Data represent fold up- 
or downregulation with p>0.05.  c. Venn diagram demonstrating the number of upregulated BCAA metabolism effectors 
in TAs of symptomatic Smn-/-;SMN2 and Smn2B/- mice. d. Weight curves of prednisolone-treated Smn2B/- mice vs. saline-
treated animals. Data represent mean ± SD; n = 10-12 animals per group; two-way ANOVA; *p<0.05; ns = not significant.  
e. Lifespan of prednisolone-treated Smn2B/- mice vs. saline-treated animals. Data represent Kaplan-Meier curves; n = 
10-12 animals per group; Log-rank (Mantel-Cox) test; p< 0.0001. f. Weight curves of Smn2B/+ mice treated with 
prednisolone or saline. Data represent mean ± SD; n = 7-10 animals per group; two-way ANOVA; ns = not significant. 
 
Fig. 6: Prednisolone treatment improves neuromuscular phenotypes in severe SMA mice. Smn-/-;SMN2 mice and 
healthy littermates were treated with 5 mg/kg prednisolone every second day beginning from P0. qPCR analysis of (a) 
MuRF-1, (b) atrogin1, (c) MyoD, (d) myogenin and (e) parvalbumin mRNAs in triceps of P7 Smn-/-;SMN2 mice and 
healthy littermates treated with prednisolone compared to untreated animals. a-e: Data represent mean ± SD; n = 3-4 
animals per group; two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; ns = not significant.  f. Motor endplate 
area in TAs of untreated and prednisolone-treated P7 Smn-/-;SMN2 mice and healthy littermates. Data represent scatter 
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plot ± SD; n = 424-711 endplates from 4 animals per group; one-way ANOVA; ****p<0.0001; ns = not significant. g. 
Quantitative analysis of motor endplate morphology (plaque-like or perforated) in TAs of untreated and prednisolone 
treated P7 Smn-/-;SMN2 mice and healthy littermates. Representative image of endplates where arrow indicates 
perforated and arrowhead indicates plaque-like. h. Quantitative analysis of the innervation status of motor endplates in 
TAs of untreated and prednisolone-treated P7 Smn-/-;SMN2 mice and healthy control littermates. Representative image 
of NMJs from untreated and prednisolone-treated Smn-/-;SMN2 mice where arrowhead indicates incomplete innervation. 
g-h. Data represent mean ± SD; n = 4 animals per group; two-way ANOVA; **p<0,01; ns = not significant. 
 
Fig. 7. Synergistic effects of Klf15 overexpression and prednisolone on disease phenotypes of severe SMA 
mice. a. qPCR analysis of Klf15 mRNA in skeletal muscle (quadriceps) from post-natal day (P) 2 and 7 Smn-/-;SMN2, 
Smn+/-;SMN2, Smn-/-;SMN2;KLF15 MTg and Smn+/-;SMN2;KLF15 MTg mice. Data represent mean ± SD; n = 3-8 
animals per group; two-way ANOVA; **p<0.01, ***p<0.001, ****p<0.0001. qPCR analysis of (b) Nr3c1, (c) GR, (d) 
GR, (e) Bcat2, (f) atrogin-1, (g) MuRF-1, (h) Myod, (i) myogenin and (j) parvalbumin mRNAs in quadriceps of P7 Smn-
/-;SMN2, Smn+/-;SMN2, Smn-/-;SMN2;KLF15 MTg and Smn+/-;SMN2;KLF15 MTg mice. b-j: Data represent mean ± SD; 
n = 6-8 animals per group; one-way ANOVA; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = not significant. k. 
Lifespan of untreated and prednisolone-treated Smn-/-;SMN2 and Smn-/-;SMN2;KLF15 MTg mice. Data represent 
Kaplan-Meier curves; n = 11-36 animals per group; Log-rank test; *p<0.05, ***p<0.001. l. Weight curves of untreated 
and prednisolone-treated Smn-/-;SMN2 and Smn-/-;SMN2;KLF15 MTg mice.  Data represent mean ± SD; n = 7-10 
animals per group; two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. m. Weight curves of untreated and 
prednisolone-treated Smn+/-;SMN2 and Smn+/-;SMN2;KLF15 MTg mice.  Data represent mean ± SD; n = 7-10 animals 
per group; two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.   
 
Fig. 8: BCAA supplementation improves disease phenotypes of severe SMA mice.  Smn-/-;SMN2 mice and healthy 
controls were treated with BCAAs (1.5 mg/kg) starting at P5. a. Weight curves of BCAA-treated Smn-/-;SMN2 mice vs. 
untreated animals. Data represent mean ± SD; n = 12-16 animals per group; two-way ANOVA; *p<0.05, ***p<0.001, 
****p<0.0001. b. Lifespan of BCAA-treated Smn-/-;SMN2 mice vs. untreated animals. Data represent Kaplan-Meier 
curves; n = 10-16 animals per group; Log-rank (Mantel-Cox) test; p = 0.0159. c. Weight curves of BCAA-treated healthy 
controls vs. untreated animals. Data represent mean ± SD; n = 14-18 animals per group; two-way ANOVA; *p<0.05, 
**p<0.01. qPCR analysis of (d) Nr3c1, (e) GR, (f) GR, (g) Klf15, (h) Bcat2, (i) MuRF-1, (j) atrogin-1, (k) MyoD, (l) 
myogenin and (m) parvalbumin mRNAs expression in triceps of BCAA-treated P7 Smn-/-;SMN2 mice and healthy 
controls compared to untreated animals. d-m: Data represent mean ± SD; n = 3-4 animals per group; two-way ANOVA; 
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**p<0.01; ns = not significant. n. Motor endplate area in TAs of BCAA-treated P7 Smn-/-;SMN2 mice and healthy 
littermates compared to untreated animals. Data represent scatter plot ± SD; n = 198-324 endplates from 4 animals per 
group; one-way ANOVA; **p<0.01, ****p<0.0001; ns = not significant.  o. Motor endplate morphology (plaque-like or 
perforated) in TAs of BCAA-treated P7 Smn-/-;SMN2 mice and healthy controls compared to untreated animals. 
Representative images of endplates from untreated and BCAA-treated Smn-/-;SMN2 mice and healthy littermates.  p. 
Innervation status of motor endplates in TAs of BCAA-treated P7 Smn-/-;SMN2 mice and healthy controls compared to 
untreated animals. Representative images of NMJs from untreated and BCAA-treated Smn-/-;SMN2 mice. o-p. Data 
represent mean ± SD; n = 4 animals per group; two-way ANOVA; *p<0.05, ***p<0.001; ns = not significant. 
Fig. 9. Schematic summarizing the aberrant effectors of the glucocorticoid (GC)-Klf15-branched-chain amino 
acid (BCAA) signaling cascade targeted by a pre-symptomatic administration of prednisolone (a) and 
symptomatic BCCA supplementation (b) and the observed effects on molecular, histological and behavioural 
disease phenotypes.  
